MARKET

CRIS

CRIS

Curis
NASDAQ
1.030
+0.040
+4.03%
After Hours: 1.030 0 0.00% 16:10 03/04 EST
OPEN
0.9899
PREV CLOSE
0.9901
HIGH
1.050
LOW
0.9872
VOLUME
40.70K
TURNOVER
--
52 WEEK HIGH
3.180
52 WEEK LOW
0.7710
MARKET CAP
14.15M
P/E (TTM)
-0.2802
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0223-0227)?
Weekly Report · 2d ago
Weekly Report: what happened at CRIS last week (0216-0220)?
Weekly Report · 02/23 09:53
Weekly Report: what happened at CRIS last week (0209-0213)?
Weekly Report · 02/16 09:52
Curis To Resale From Time To Time Up To 107,706,700 Shares Of Common Stock By The Selling Stockholders
Benzinga · 02/13 21:25
Curis files to sell 107.71M shares of common stock for holders
TipRanks · 02/13 21:25
CURIS INC - TO RESALE FROM TIME TO TIME UP TO 107,706,700 SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 02/13 21:23
Curis Regains Nasdaq Compliance, Remains Under Monitoring Period
TipRanks · 02/09 22:19
Curis Inc. gibt Termin für Sonderaktionärstreffen bekannt
Reuters · 02/09 21:56
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.